Demographic data: mean (minimum, maximum) | |
Age (years) | 75 (50, 97) |
Weight (kg) | 81 (45, 160) |
Height (cm) | 175 (157, 198) |
Diagnosis/findings: mean | |
Time since first diagnosis (months) | 33 |
Biopsy: Number of cores | 8.2 |
āāāNumber of positive cores | 4.5 |
cT1-2, % | 44 |
cT3-4, % | 32 |
M+, % | 20 |
Gleason grade (1-5) | 3.4 |
Gleason sum (2-10) | 6.8 |
Therapy with GnRH analogues: number of patients (%) | |
First-time treatment | 610 (48) |
Pre-treatment* | 652 (51) |
āāā3 monthly leuprolide acetate | 210 (32.2) |
āāāLeuprolide acetate, Takeda Pharmaceutical | 168 (25.8) |
āāāGoserelin acetate, AstraZenca | 107 (16.4) |
āāāBuserelin acetate, Sanofi-Aventis | 97 (14.9) |
āāā1 monthly leuprolide acetate | 27 (4.1) |
āāāLeuprorelin acetate, Takeda Pharmaceutical | 21 (3.2) |
āāāOther drugs | 22 (3.4) |
āāāMissing data | 15 (2.3) |